WELCOME
  • Home
    • About the Haplo SCD Consortium
  • Patients & Families
    • Disease Information >
      • Signs and Symptoms
      • Treatment Options
    • Parent-To-Child (Haplo) Transplant >
      • Haplo Transplant Overview
      • Benefits of Haploidentical Donors
      • Meet a Donor
      • Meet a Patient
      • Trial Eligibility
      • Transplant Facilities Near You >
        • Travel and Housing
    • Video Education
    • Patient Advocacy Groups
    • Resources & External Links
  • Healthcare Professionals
    • Trial Aims and Hypotheses
    • Trial Eligibility
    • Preparative Regimen
    • Clinical Sites
    • Core Services
  • News & Events
  • Contact Us
Picture
About the Consortium

The Haplo SCD Consortium was developed to provide resources to families, patients, and physicians pursuing Familial Haploidentical transplantation for SCD.

We have developed a consortium of seven clinical transplant sites, three processing centers, and cores in donor chimerism, anti-HLA antibodies, immunology, cell processing, biostatistics, neuroimaging, neurocognition, quality of life, pulmonary function, pulmonary vascular, radiation therapy. We've also partnered with the Children’s Sickle Cell Foundation, and the Sickle Cell Disease Association of Illinois (SCDAI) to help educate patients and their families regarding sickle cell disease and familial haploidentical stem cell transplant.

The Collaborating Centers have joined efforts on the protocol The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults with Sickle Cell Disease or Beta Thalassemia Following Myeloablative Conditioning (MAC) and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback (IND 127812).

​
Please contact Principal Investigator Mitchell Cairo, MD for additional information or any of the seven clinical transplant sites to refer patients.


Program Structure
Collaborating Centers
Haplo Sickle Cell Disease Consortium
Contact Us       About Us